Other targets that have been studied in MM, such as GPRC5D, FCHR5, and CS1/SLAM F7, may also be important in patients with AL amyloidosis, and novel therapies directed at these antigens may further expand the treatment armamentarium. Here, SLAMF1 is linked to AL amyloidosis.